KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced positive phase 1 data for an orally disintegrating tablet (ODT) formulation for its lead compound sebetralstat. Sebetralstat is currently being developed in the phase 3 KONFIDENT clinical trial as a potential on-demand treatment for hereditary angioedema (HAE) attacks.
https://finance.yahoo.com/news/kalvista-pharmaceuticals-announces-positive-phase-104500309.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.